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Objective. To compare major clinical outcomes after successful percutaneous coronary intervention (PCI) with first-generation
(1G) drug-eluting stents (DES) and second-generation (2G) DES in patients with acute myocardial infarction (AMI) and
prediabetes. Background. Patients with prediabetes are associated with an increased incidence of coronary artery disease. *e
relative superiority of 1G- and 2G-DES in these patients is not well established. Methods. A total of 4997 patients with AMI and
prediabetes were divided into two groups: the 1D-DES group (n= 726) and the 2G-DES group (n= 4271). *e primary outcomes
were the patient-oriented composite outcomes (POCOs) defined as all-cause death, recurrent myocardial infarction (Re-MI), and
any disease revascularization at 2-year follow-up. *e secondary outcome was probable or definite stent thrombosis (ST). Results.
After propensity score-matching (PSM) analysis, two PSM groups (698 pairs, n= 1396, C-statistics = 0.725) were generated. *e
cumulative incidence rates of POCOs (hazard ratio (HR): 1.467; 95% confidence interval (CI): 1.068–2.015; p � 0.018), any disease
revascularization (HR: 2.259; 95% CI: 1.397–3.654; p � 0.001), and ST (HR: 4.361; 95% CI: 1.243–15.30; p � 0.021) in the 1G-DES
group were significantly higher than those in the 2G-DES group. However, the cumulative incidence rates of all-cause death,
cardiac death, and Re-MI were similar between the two groups. Conclusions. In patients with AMI and prediabetes, 2G-DES
implantation was more efficacious than 1G-DES implantation over a 2-year follow-up period. However, further studies are needed
to confirm these results.
1. Introduction
In the fibrinolytic era, hyperglycemia, rather than normo-
glycemia, was a major independent prognostic factor of
adverse clinical outcomes in patients with acute myocardial
infarction (AMI) [1, 2]. Similarly, in the drug-eluting stent
(DES) era, hyperglycemia is an independent predictor of
early and late mortality in patients with ST-segment
elevation myocardial infarction (STEMI) regardless of the
presence or absence of known diabetes [3, 4]. *e exact
mechanisms by which hyperglycemia is associated with
adverse major clinical outcomes in AMI have not been fully
elucidated yet. With regard to diabetes mellitus (DM), many
studies have shown its association with higher long-term risk
of death, myocardial infarction (MI), and repeat revascu-
larization in patients undergoing percutaneous coronary
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intervention (PCI) [5–7]. Patients with prediabetes are at an
increased risk of cardiovascular disease (CVD), and predi-
abetes is associated with an increased incidence of coronary
artery disease (CAD) [8, 9]. Even though the relative su-
periority between the first-generation (1G) and second-
generation (2G) DESs in patients with AMI is controversial
[10–12], most previous studies were not performed under
the circumstance of prediabetes. *erefore, the comparative
long-term clinical outcomes between the two DES genera-
tions were limited. Hence, we investigated and compared the
major clinical outcomes after successful PCI with 1G-DES
and 2G-DES in patients with AMI and prediabetes over a 2-
year follow-up period.
2. Methods
2.1. Study Population. *is study was a nonrandomized,
multicenter, observational, and retrospective cohort study. A
total of 45863 patients from the Korea AMI Registry (KAMIR)
who had AMI and underwent successful stent implantation
between November 2005 and June 2015 were evaluated.
KAMIR is the first nationwide and multicenter registry that
included >50 community and teaching hospitals in South
Korea since November 2005 [13]. Eligible patients were aged
≥18 years at the time of hospital admission. Among the pa-
tients, those with incomplete laboratory results, including
unidentified blood hemoglobin (Hb) A1c and blood glucose
test results (n=27737, 60.5%), those whowere lost to follow-up
(n=3275, 7.1%), those who received a bare-metal stent
(n=297, 0.6%), those with concomitant use of 1G-DES and
2G-DES (n=174, 0.4%), those with normoglycemia (n=3845,
8.4%), those with DM (n=5291, 11.5%), and those with car-
diogenic shock (n=247, 0.5%) were excluded. Finally, 4997
patients with AMI and prediabetes who underwent successful
DES implantation were included in the study. *e patients
were divided into two groups: the 1G-DES group (n=726,
14.5%; sirolimus-eluting stent (SES; Cypher, Cordis Corp.,
Miami Lakes, Florida; n=313, 43.1%) and paclitaxel-eluting
stent (PES, Taxus, Boston Scientific, Natick, Massachusetts;
n=413, 56.9%)) and the 2G-DES group (n=4271, 85.5%;
zotarolimus-eluting stent (ZES; Resolute Integrity, Medtronic,
Inc., Minneapolis, MN; n=1466, 34.3%), everolimus-eluting
stent (EES; Xience Prime, Abbott Vascular, Santa Clara, CA; or
Promus Element, Boston Scientific, Natick, MA; n=2132,
49.9%), biolimus-eluting stent (BES; BioMatrix Flex, Biosen-
sors International, Morges, Switzerland; or Nobori, Terumo
Corporation, Tokyo, Japan; n=577, 13.5%), and other stents
(n=96, 2.2%); Figure 1). *e study protocol was approved by
the institutional review board of each participating center, and
the study was conducted in accordance with the principles of
the 1975Declaration of Helsinki. In this retrospective study, we
evaluated patients who had provided written informed consent
prior to participation in the KAMIR study. *erefore, any
information concerning adverse events of these 4997 partici-
pants with AMI and prediabetes including the time intervals
and the types of events after the index PCI, which occurred
during a 2-year follow-up period, was monitored at the out-
patient clinic, by phone calls, or by reviewing their charts at
each participating center in those days.
2.2. Percutaneous Coronary Intervention and Medical
Treatment. Coronary angiography and PCI were performed
in accordance with the general guideline [14]. Before PCI, all
the patients received loading doses of aspirin 200–300mg
and clopidogrel 300–600mg; alternatively, ticagrelor 180mg
or prasugrel 60mg was administered. Dual antiplatelet
therapy (DAPT; a combination of aspirin 100mg/day with
clopidogrel 75mg/day or ticagrelor 90mg twice daily or
prasugrel 5–10mg/day) for> 12months was recommended
for patients who underwent PCI. Administration of triple
antiplatelet therapy (cilostazol (Pletal®, Otsuka Pharma-ceutical Co., Tokyo, Japan) 100mg twice daily added to
DAPT) was left to the discretion of the individual physicians.
2.3. Study Definitions and Clinical Outcomes. Prediabetes
was determined based on the medical history and glycated
hemoglobin (HbA1c) and fasting plasma glucose (FPG)
levels at the index hospitalization and defined as an HbA1c
level of 5.7%–6.4% and an FPG level of 100–125mg/dL
(5.6–6.9mmol/L) [15]. ST-segment elevation myocardial
infarction (STEMI) and non-STEMI were defined in ac-
cordance with the current guidelines [16, 17]. In NSTEMI
cases, an early invasive treatment strategy was defined as
performing PCI within 24 hours after admission [17]. A
successful PCI was defined as a residual stenosis of <30%
and thrombolysis in myocardial infarction (TIMI) with
grade III flow for the infarct-related artery (IRA) after the
procedure. *e primary clinical outcome of this study was
the occurrence of patient-oriented composite outcomes
(POCOs) defined as all-cause death, recurrent myocardial
infarction (Re-MI), or any disease revascularization (ADR)
at 2-year follow-up. *e secondary outcome was definite or
probable stent thrombosis (ST) at 2-year follow-up. All-
cause death was classified as cardiac death (CD) or non-
CD. ADR was composed of target lesion revascularization
(TLR), target vessel revascularization (TVR), and non-
TVR. *e definitions of Re-MI, TLR, TVR, and non-TVR
were previously published [18]. *e cumulative incidence
of STwas defined by current consensus as acute (0 to 24 h),
subacute (24 h to 30 days), late (30 days to 1 year), and very
late (>1 year) [19].
2.4. Statistical Analyses. For continuous variables, in this
study, the normality test was performed using the Kol-
mogorov–Smirnov normality test. According to the nor-
mality results, the independent samples t-test was applied
to examine the difference of continuous variables means of
the two groups, and the data were expressed as the
mean± standard deviations. For categorical variables, the
differences between the two groups were analyzed using the
chi-squared test or, if not applicable, Fisher’s exact test, and
the data were expressed as counts and percentages. To
adjust for potential confounders, a propensity score-
matching (PSM) analysis was performed using a logistic
regression model. We tested all available variables listed in
Table 1 that could be of potential relevance. *e C-statistics
for PSM was 0.725 in the current study. Patients in the 1G-
DES group were then one-to-one matched to those in the
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Table 1: Baseline clinical, laboratory, and procedural characteristics.
Variables
All patients Propensity score-matched patients
1G-DES (n� 726) 2G-DES (n� 4271) p value 1G-DES (n� 698) 2G-DES (n� 698) p value
Age (years) 63.8± 12.1 64.2± 12.4 0.464 63.9± 12.0 63.7± 12.8 0.814
Men, n (%) 535 (73.7) 3169 (74.2) 0.773 516 (73.9) 520 (74.5) 0.854
LVEF (%) 52.6± 12.4 52.4± 11.2 0.798 52.7± 12.54 52.4± 11.5 0.618
BMI (kg/m2) 24.1± 3.1 24.1± 3.3 0.854 24.1± 2.9 24.1± 3.1 0.927
SBP (mmHg) 133.7± 24.8 132.3± 25.2 0.150 133.2± 24.2 134.1± 25.5 0.502
DBP (mmHg) 82.0± 14.5 80.1± 15.0 0.003 81.5± 13.9 81.6± 15.7 0.866
STEMI, n (%) 405 (55.8) 2442 (57.2) 0.484 391 (56.0) 394 (56.4) 0.871
Primary PCI, n (%) 376/405 (92.8) 2346/2442 (96.1) 0.003 363/391 (92.8) 371/394 (94.2) 0.452
NSTEMI, n (%) 321 (44.2) 1829 (42.8) 0.484 307 (44.0) 304 (43.6) 0.871
PCI within 24 hours 246/321 (76.6) 1563/1829 (85.5) <0.001 239/307 (77.9) 239/304 (78.6) 0.818
CPR on admission 17 (2.3) 181 (4.2) 0.013 17 (2.4) 16 (2.3) 0.860
Hypertension, n (%) 362 (49.9) 2087 (48.9) 0.619 351(50.3) 346 (49.6) 0.789
Dyslipidemia, n (%) 70 (9.6) 503 (11.8) 0.095 70 (10.0) 72 (10.3) 0.859
Previous MI, n (%) 20 (2.8) 131 (3.1) 0.649 19 (2.7) 15 (2.1) 0.603
Previous PCI, n (%) 41 (5.6) 228 (5.3) 0.733 40 (5.7) 33 (4.7) 0.471
Previous CABG, n (%) 3 (0.4) 13 (0.3) 0.631 3 (0.4) 2 (0.3) 0.654
Previous CVA, n (%) 45 (6.2) 253 (5.9) 0.773 43 (6.2) 37 (5.3) 0.565
Previous HF, n (%) 8 (1.1) 48 (1.1) 0.959 8 (1.1) 5 (0.7) 0.579
Current smokers, n (%) 293 (40.4) 1875 (43.98) 0.075 280 (40.1) 307 (44.0) 0.143
Peak CK-MB (mg/dL) 127.8± 208.2 136.4± 196.5 0.278 129.4± 210.2 119.5± 141.6 0.301
Peak troponin-I (ng/mL) 39.3± 88.9 46.1± 120.4 0.178 40.4± 83.0 39.7± 59.3 0.869
NT-proBNP (pg/mL) 2141.2± 5100.7 1852.1± 4784.8 0.232 2044.5± 4062.4 1997.2± 3788.8 0.821
hs-CRP (mg/dL) 12.9± 36.8 9.7± 53.4 0.145 12.1± 31.3 14.1± 85.9 0.550
Serum creatinine (mg/L) 1.11± 1.03 1.10± 1.52 0.935 1.11± 1.03 1.22± 2.77 0.314
Serum glucose (mg/dL) 149.3± 48.9 150.4± 50.8 0.590 149.1± 47.6 151.4± 49.9 0.381
Total cholesterol (mg/dL) 188.1± 43.4 186.9± 44.4 0.494 187.9± 43.3 185.8± 42.0 0.360
Triglyceride (mg/L) 117.9± 75.6 131.9± 102.2 <0.001 118.8± 75.7 120.3± 67.1 0.698
HDL cholesterol (mg/L) 45.0± 12.8 43.6± 15.4 0.020 44.8± 12.3 44.1± 15.4 0.380
LDL cholesterol (mg/L) 121.0± 36.7 119.5± 43.3 0.361 120.7± 38.6 118.7± 36.1 0.300
Discharge medications
Aspirin, n (%) 684 (94.2) 4119 (96.4) 0.004 658 (94.3) 654 (93.7) 0.653
Clopidogel, n (%) 707 (97.4) 3674 (86.0) <0.001 680 (97.4) 680 (97.4) 1.000
A total of 45863 AMI patients who underwent successful stent implantation from 
November 2005 to June 2015 in the KAMIR were eligible 
Exclusion
Incomplete laboratory results including unidentified blood 
HbA1c and blood glucose test results (n = 27737)
Lost to follow-up (n = 3275)
BMS (n = 297)
Concomitant use of 1G-DES and 2G-DES (n = 174)
Normoglycemia (n = 3845)
Diabetes mellitus (n = 5291)
Cardiogenic shock (n = 247)
Finally, a total of 4997 patients with AMI and prediabetes who underwent successful DES 
implantation were included
1G-DES (n = 726) 2G-DES (n = 4271)









Figure 1: Study flowchart. AMI: acute myocardial infarction; KAMIR: Korea AMI Registry; HbA1c: hemoglobin A1c; BMS: bare-metal
stent; 1G: first-generation; 2G: second-generation; DES: drug-eluting stent; PSM: propensity score-matching analysis.
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2G-DES group according to propensity scores with the
nearest available pair-matching method. Subjects were
matched with a caliper width equal to 0.01. *e procedure
yielded 698 matched pairs. Various clinical outcomes were
estimated using the Kaplan–Meier method, and differences
between the two groups were compared using the log-rank
test. For all analyses, two-sided values of p< 0.05 were
considered statistically significant. All statistical analyses
were performed using the SPSS version 20 software (IBM;
Armonk, NY, USA).
3. Results
3.1. Baseline Characteristics. *e baseline clinical, labora-
tory, and procedural characteristics of the study population
are summarized in Table 1. *e mean age (63.8 ± 12.1 years
Table 1: Continued.
Variables
All patients Propensity score-matched patients
1G-DES (n� 726) 2G-DES (n� 4271) p value 1G-DES (n� 698) 2G-DES (n� 698) p value
Ticagrelor, n (%) 3 (0.4) 363 (8.5) <0.001 3 (0.4) 4 (0.6) 0.705
Prasugrel, n (%) 2 (0.3) 194 (4.5) <0.001 2 (0.3) 2 (0.3) 1.000
Cilostazol, n (%) 217 (29.9) 812 (19.0) <0.001 197 (28.2) 213 (30.5) 0.378
BB, n (%) 573 (78.9) 3552 (83.2) 0.005 552 (79.1) 571 (81.8) 0.200
ACEI, n (%) 419 (57.7) 2311 (54.1) 0.071 396 (56.7) 393 (56.3) 0.871
ARB, n (%) 178 (24.5) 1101 (25.8) 0.472 174 (24.9) 171 (24.5) 0.901
CCB, n (%) 54 (7.4) 240 (5.6) 0.054 48 (6.9) 50 (7.2) 0.917
Lipid-lowering agents, n (%) 535 (73.7) 3673 (86.0) <0.001 530 (75.9) 542 (77.7) 0.447
Infarct-related artery
Left main, n (%) 18 (2.5) 77 (1.8) 0.217 14 (2.0) 168 (2.3) 0.712
LAD, n (%) 363 (50.0) 2147 (50.3) 0.878 349 (50.0) 340 (48.7) 0.630
LCx, n (%) 134 (18.5) 706 (16.5) 0.199 130 (18.6) 128 (18.3) 0.890
RCA, n (%) 211 (29.1) 1341 (31.4) 0.209 204 (29.2) 213 (30.5) 0.590
Treated vessel
Left main, n (%) 25 (3.4) 127 (3.0) 0.495 21 (3.0) 24 (3.4) 0.649
LAD, n (%) 443 (61.0) 2537 (59.4) 0.411 424 (60.7) 434 (62.2) 0.582
LCx, n (%) 207 (28.5) 1106 (25.9) 0.139 197 (28.2) 191 (27.4) 0.720
RCA, n (%) 262 (36.1) 1624 (38.0) 0.320 255 (36.5) 265 (38.0) 0.580
ACC/AHA lesion type
Type B1, n (%) 113 (15.6) 580 (13.6) 0.153 110 (15.8) 115 (16.5) 0.716
Type B2, n (%) 237 (32.6) 1367 (32.0) 0.734 226 (32.4) 231 (33.1) 0.776
Type C, n (%) 266 (36.6) 1877 (43.9) <0.001 262 (37.5) 248 (35.5) 0.436
Extent of CAD
1-vessel, n (%) 321 (44.2) 2165 (50.7) <0.001 303 (43.4) 296 (42.4) 0.705
2-vessel, n (%) 224 (30.9) 1326 (31.0) 0.917 217 (31.1) 242 (34.7) 0.154
≥3-vessel, n (%) 181 (24.9) 780 (18.3) <0.001 171 (24.5) 160 (22.9) 0.489
IVUS 177 (24.4) 1007 (23.6) 0.638 172 (24.6) 159 (22.8) 0.413
OCT 0 (0.0) 33 (0.8) 0.017 0 (0.0) 0 (0.0) —
FFR 1 (0.1) 59 (1.4) 0.004 1 (0.1) 0 (0.0) 0.317
Stents
SES, n (%) 313 (43.1) 303 (43.4)
PES, n (%) 413 (56.9) 395 (56.6)
ZES, n (%) 1466 (34.3) 237 (34.0)
EES, n (%) 2132 (49.9) 366 (52.4)
BES, n (%) 577 (13.5) 73 (10.5)
Others, n (%) 96 (2.2) 22 (3.1)
Stent diameter (mm) 3.13± 0.42 3.13± 0.42 0.987 3.13± 0.41 3.14± 0.43 0.592
Stent length (mm) 25.9± 7.15 26.9± 11.5 0.031 25.9± 7.06 25.9± 10.0 0.907
Number of stents 1.54± 0.84 1.48± 0.80 0.051 1.54± 0.80 1.55± 0.84 0.740
Values are means ± SD or numbers and percentages. *e p values for categorical data were obtained from the chi-square or Fisher’s exact test. For
continuous variables, differences between the two groups were evaluated with independent samples t-test. LVEF: left ventricular ejection fraction;
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; STEMI: ST-segment elevation myocardial infarction; NSTEMI:
non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CPR: cardiopulmonary resuscitation; CABG: coronary
artery bypass graft; CVA: cerebrovascular events; HF: heart failure; CK-MB: creatine kinase myocardial band; NT-proBNP: N-terminal pro-brain
natriuretic peptide; hs-CRP: high-sensitivity C-reactive protein; HDL: high-density lipoprotein; LDL: low-density lipoprotein; BB: beta-blocker;
ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blocker; CCB: calcium channel blockers; LAD: left anterior descending
coronary artery; LCx: left circumflex coronary artery; RCA: right coronary artery; ACC/AHA: American College of Cardiology/American Heart
Association; CAD: coronary artery disease; IVUS: intravascular ultrasound; OCT: optical coherence tomography; FFR: fractional flow reserve; SES:
sirolimus-eluting stent; PES: paclitaxel-eluting stent; ZES: zotarolimus-eluting stent; EES: everolimus-eluting stent; BES: biolimus-eluting stent.
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vs. 64.2± 12.4 years, p � 0.464) and proportion of men
(73.7% vs. 74.2%, p � 0.773) of the enrolled patients were
similar between the two groups. *e mean left ventricular
ejection fraction (LVEF) was not significantly different
between the two groups (52.6% ± 12.4% vs. 52.4% ± 11.2%,
p � 0.798) and was >50% in both groups. However, the
proportion of patients who underwent primary PCI (92.8%
vs. 96.1%, p � 0.003) or PCI within 24 hours (76.6% vs.
85.5%, p< 0.001) was significantly higher in the 2G-DES
group than in the 1G-DES group. *e proportion of pa-
tients with cardiopulmonary resuscitation (CPR) on ad-
mission (4.2% vs. 2.3%, p � 0.013) and the prescription
rates of aspirin, ticagrelor, prasugrel, and lipid-lowering
agents as discharge medications; the number of American
College of Cardiology/American Heart Association (ACC/
AHA) type C lesions; the incidence of single-vessel disease;
the use frequency of optical coherence tomography and
fractional flow reserve; and the mean total length of the
deployed stents were significantly greater in the 2G-DES
group than in the 1G-DES group. By contrast, the pre-
scription rates of clopidogrel and cilostazol as discharge
medications and the incidence of ≥ 3-vessel disease were
significantly higher in the 1G-DES group than in the 2G-
DES group. However, these intergroup differences in
baseline characteristics were well balanced after PSM
adjustment.
3.2. Clinical Outcomes. *e cumulative incidences of major
clinical outcomes at 2 years are listed in Table 2 and Figure 2.
After PSM analysis, the cumulative incidence rates of
POCOs (hazard ratio (HR): 1.467; 95% confidence interval
(CI): 1.068–2.015; p � 0.018), ADR (HR: 2.259; 95% CI:
1.397–3.654; p � 0.001), and ST (HR: 4.361; 95% CI:
1.243–15.30; p � 0.021) were significantly higher in the 1G-
DES group than in the 2G-DES group. However, the cu-
mulative incidence rates of all-cause death, CD, and Re-MI
were similar between the two groups. Table 3 shows the
independent predictors of POCOs and ADR at 2 years. Old
age (≥65 years), LVEF of <50%, CPR on admission, use of a
lipid-lowering agent, and multivessel disease were signifi-
cant independent predictors of POCOs. In addition, mul-
tivessel disease was a significant independent predictor of
ADR in this study.
4. Discussion
*e main findings of this study are as follows: (1) the cu-
mulative incidence rates of POCOs, ADR, and ST were
significantly higher in the 1G-DES group than in the 2G-
DES group; (2) the cumulative incidence rates of all-cause
death, CD, and Re-MI were similar between the two groups;
(3) Multivessel disease was a common independent pre-
dictor of both POCOs and ADR.
1G-DES is made of stainless steel with a closed-cell design
and has a relatively thick inner diameter (130–150μm), making
them difficult to maneuver through significantly diseased and
calcified vessels. In addition, the major serious problem of the
1G-DES was the occurrence of (very) late ST, induced by the
polymer or even by the stent material itself [20]. By contrast,
the 2G-DES is made of cobalt-chromium (CoCr) and has
thinner stent struts (50–90μm) and showed improved ability
for deliverability while maintaining an adequate radial strength
[21]. *e polymers in the 2G-DES were more biocompatible
and thromboresistant than those in the 1G-DES [22] One
meta-analysis revealed that CoCr-EESs were associated with
significantly lower rates of definite ST than PESs (odds ratio
(OR): 0.34, 95% CI: 0.19–0.62) [23]. With regard to diabetes,
Bavishi et al. [24] performed a meta-analysis of randomized
trials to compare the efficacy and safety between the 1G-DES
and the 2G-DES. In their study, the EES showed significantly
decreased incidence rates of major adverse cardiac events by
18% (relative risk (RR)): 0.82, 95% CI: 0.70–0.96) and ST by
46% (RR: 0.54, 95% CI: 0.35–0.82) as compared with the 1G-
DES. Moreover, the EES showed a trend toward reduced in-
cidence rates of TLR and TVR (p � 0.05). *e ZES was as-
sociated with 89% increased risk of TLR (RR: 1.89, 95% CI:
1.10–3.22) as compared with the 1G-DES in their study. *e
results of our study may be similar to those of their study.
However, their study population was not confined to patients
with AMI.
Higher blood glucose level was an important factor of
increased risk of death and poor clinical outcome after AMI
[25–27]. Kowalczyk et al. [28] reported that patients with
HbA1c levels of ≤5.9% had significantly lower posthospital
mortality (4.5%) than those with HbA1c levels of >5.9%
(25.0%; p< 0.001) in 2146 AMI survivors. However, the
evident underlying pathological mechanisms related to the
adverse clinical outcomes in hyperglycemia status remain
unclear. Liu et al. [29] suggested that elevated glucose level is
associated with the development of endothelial dysfunction.
Moreover, this endothelial dysfunction is the leading cause
of platelet activation [30]. In addition, hyperglycemia plays
an important role in the development of diabetic macro-
vascular complications, including atherosclerosis and
restenosis [31]. Patients with diabetes have more diffuse
disease that often rapidly progresses and tend to have ex-
aggerated neointimal hyperplasia and increased need for
repeat revascularization [32]. Moreover, glycosylation of
vascular collagen and elastin is thought to lead to a more
diffuse pattern of restenosis [33].
Even though the 2G-DES uses an evolved stent platform
and a more biocompatible polymer than that in the 1G-DES,
data concerning the outcomes between the two DESs in
patients with AMI are conflicting [10, 34]. With regard to
diabetes, the relative superiority between the 1G-DES and the
2G-DES in patients with diabetes is controversial [35–37].
Furthermore, in patients with prediabetes, limited follow-up
data are available regarding the comparative long-term effects
of 1G-DES and 2G-DES implantation. Even though the study
population, follow-up duration, and definition of prediabetes
were different between in our study and that of Kok et al. [38],
clinical outcomes were compared between prediabetes and
diabetes (11.1% vs. 10.5%). *erefore, the major clinical
outcomes of our study could reflect the meta-analysis results
of the study of Bavishi et al. [24].
ST is another controversial issue in the DES era. In our
study, unexpectedly, the cumulative incidence of very late ST
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Table 2: Clinical outcomes by Kaplan–Meier analysis and Cox proportional hazard ratio analysis at 2 years.
Outcomes 1G-DES 2G-DES Log-rank Hazard ratio (95% CI) p value
All patients
POCOs 100 (13.9) 353 (8.8) <0.001 1.616 (1.294–2.017) <0.001
All-cause death 43 (5.9) 171 (4.2) 0.035 1.431 (1.024–1.999) 0.036
Cardiac death 34 (4.7) 129 (3.1) 0.030 1.514 (1.037–2.209) 0.032
Re-MI 9 (1.3) 79 (2.0) 0.192 1.576 (0.791–3.141) 0.196
Death or MI 52 (7.2) 244 (6.0) 0.224 1.204 (0.892–1.624) 0.225
aAny disease revascularization 58 (8.4) 138 (3.6) <0.001 2.383 (1.752–3.238) <0.001
Stent thrombosis (probable or definite) 14 (1.9) 28 (0.7) 0.001 2.956 (1.556–5.615) 0.001
Acute 1 (0.1) 2 (0.0) 0.355 2.941 (0.267–32.44) 0.378
Subacute 4 (0.6) 13 (0.3) 0.290 1.814 (0.591–5.563) 0.298
Late 7 (1.0) 10 (0.2) 0.002 4.146 (1.578–10.89) 0.004
Very late 2 (0.3) 3 (0.1) 0.103 3.967 (0.663–23.74) 0.131
Propensity score-matched patients
POCOs 94 (13.5) 64 (9.5) 0.017 1.467 (1.068–2.015) 0.018
All-cause death 42 (6.0) 36 (5.3) 0.541 1.149 (0.736–1.793) 0.541
Cardiac death 33 (4.8) 25 (3.7) 0.317 1.303 (0.775–2.191) 0.319
Re-MI 8 (1.2) 8 (1.2) 0.971 1.019 (0.382–2.714) 0.971
Death or MI 50 (7.2) 44 (6.5) 0.588 1.118 (0.746–1.677) 0.588
aAny disease revascularization 54 (8.2) 24 (3.7) 0.001 2.259 (1.397–3.654) 0.001
Stent thrombosis (probable or definite) 13 (1.9) 3 (0.4) 0.012 4.361 (1.243–15.30) 0.021
Acute 1 (0.1) 0 (0.0) 0.317 — —
Subacute 3 (0.4) 1 (0.1) 0.316 3.006 (0.313–28.90) 0.340
Late 7 (1.0) 2 (0.3) 0.093 3.526 (0.733–16.98) 0.116
Very late 2 (0.3) 0 (0.0) 0.155 — —
1G: first-generation; 2G: second-generation; DES: drug-eluting stent; HR: hazard ratio; CI: confidence interval; POCOs: patient-oriented composite
outcomes; Re-MI: recurrent myocardial infarction. aAny disease revascularization was composed of target lesion revascularization, target vessel revas-
cularization, and nontarget vessel revascularization.
Table 3: Independent predictors for POCOs and any disease revascularization at 2 years in all patients.
Variables
POCOs Any disease revascularization
Univariate Multivariate Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
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was similar between the two DES generations. By contrast,
late ST was significantly different between the two groups.
*e main cause of these results may be related to the
relatively higher numbers of patients who received EES (n=
2132/4271, 49.9% ) in this study population. In the study of
Bangalore et al. [39], EES was associated with the lowest
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Figure 2: Kaplan–Meier analysis of the incidence rates of POCOs (a, b), all-cause death (c, d), cardiac death (e, f ), Re-MI (g, h), any disease
revascularization (i, j), and ST (k, l) in all patients (a, c, e, g, i, k) and PSM patients (b, d, f, h, j, l) at 2 years. 1G: first-generation; 2G: second-
generation; DES: drug-eluting stent; HR: hazard ratio; CI: confidence interval; POCOs: patient-oriented composite outcomes; Re-MI:
recurrent myocardial infarction; ST: stent thrombosis; PSM: propensity score-matching analysis.
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incidence rates of TVR, Re-MI, and ST as compared with
ZES and PES. In the study of Kedhi et al. [35], the difference
in the risk of STwas already observed in the early phase and
was maintained during the 1-year follow-up. Similarly, in
our study, the risk of ST was already determined within 1
year after the index PCI.
Although oral glucose tolerance test (OGTT) is con-
sidered more sensitive than measurement of HbA1c level for
defining diabetes [15], in this study, prediabetes was de-
termined on the basis of patients’ medical history and
HbA1c and FPG levels at the index hospitalization. One of
the main advantages of measuring HbA1c level is that it can
be performed at any time because it does not require fasting.
*is is especially convenient in circumstances in which
performing the test and interpreting the result may be
difficult in the milieu of an acute illness such as AMI [38, 40].
*erefore, despite that measurement of HbA1c level may not
be ideal, it can be used as an alternative diagnostic tool for
making these important assessments.
In this KAMIR study, >50 high-volume university or
community hospitals in South Korea participated, but the
study population was insufficient to provide meaningful
results. Taken together, the results of this study may provide
a meaningful message to the interventional cardiologist
during PCI to help select the appropriate DES, especially in
patients with AMI and prediabetes.
*is study has several limitations. First, some datamay have
been underreported and/or missing owing to the non-
randomized nature of this study. Second, a proportion of the
patients with prediabetes (based on HbA1c level) may be di-
agnosed with overt diabetes if retested using a more sensitive
diagnostic test (e.g., OGTT).*is may be a source of bias in the
study. *ird, the study was based on discharge medications, as
we could not confirm the participants’ adherence or non-
adherence to their antidiabetic drugs. *erefore, we could not
discern the degree of glycemic control of the participants during
the follow-up period, which might constitute an additional bias
in this study. Fourth, the 2-year follow-up period was relatively
short for determining the long-term major clinical outcomes;
thus, longer follow-up period data are required. Fifth, we
performed a PSM analysis to strengthen our results, but vari-
ables not included in the KAMIR study may have affected the
study outcomes.
In conclusion, with regard to the beneficial effects on
POCOs, ADR, and ST reduction capacity, in patient with AMI
and prediabetes, 2G-DES implantation was more efficacious
than 1G-DES implantation during the 2-year follow-up period.
However, further randomized trials are needed to more pre-
cisely confirm the superior efficacy of 2G-DES over 1G-DES.
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